期刊文献+

人乳头瘤病毒疫苗研究进展 被引量:2

Research progress In vaccines against human papillomavtrus
原文传递
导出
摘要 2006年6月美国FDA批准了第一个用于预防宫颈癌的疫苗,即可以预防人乳头瘤病毒(human papillomavirus。HPV)6、11、16和18型感染的四价疫苗,70%的宫颈癌和90%的生殖器疣由这些型别引起。还有一种可以预防HPV16和18型的二价HPV疫苗也已上市。此文主要就治疗性和预防性HPV疫苗的发展情况做一综述。 The US Food and Drug Administration licensed the first vaccine to prevent cervical cancers in women in June 2006. The quadrivalent vaccine protects against human papillomavirus (HPV)-6, -11, -16, and -18, which are responsible for 70% of cervical cancers and 90% of genital warts. The second is a bivalent vaccine preventing from infection of two high-risk oncogenic HPV types (16 and 18 ). This article reviews the biology of HPV that allows for the development of both therapeutic and prophylactic vaccines.
出处 《国际生物制品学杂志》 CAS 2009年第2期83-86,共4页 International Journal of Biologicals
关键词 宫颈肿瘤 乳头瘤病毒疫苗 临床研究 HPV疫苗 Uterine cervical neoplasms Papillomavirus vaccines
  • 相关文献

参考文献16

  • 1Clifford GM, Smith JS, Plummer M, et al. Human papillomavims types in invasive cervical cancer worldwide: a meta-analysis [J]. Br J Cancer, 2003, 88(1):63-73.
  • 2Tovar JM, Bazaldua OV, Vargas L, et al. Human papillomavirus, cervical cancer, and the vaccines [ J]. Postgrad Med, 2008, 120(2) :79-84.
  • 3Wang KL. Human papiUomavirus and vaccination in cervical cancer [J]. Taiwan J Obstet Gynecol, 2007, 46(4) :352-362.
  • 4Gillison ML. Human papillomavims-related diseases: ompharynx cancers and potential implications for adolescent HPV vaccination [J]. J Adolesc Health, 2008, 43(4 Suppl) :S52-60.
  • 5Dinh TA, Benoit MF. Human papillomavirus vaccine: progress and the future [J]. Expert Opin Biol Ther, 2007, 7(4) :479- 485.
  • 6Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine [ J]. J Natl Cancer Inst, 2001, 93 (4) :284-292.
  • 7Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomized control trial [ J ]. Lancet, 2006, 367 ( 9518 ) : 1247-1255.
  • 8Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective [ J]. Int J Cancer, 2004, 111 (2) :278- 285.
  • 9Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [ J ]. Lancet, 2004, 364 ( 9447 ) : 1757-1765.
  • 10Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase Ⅲ double-blind, randomised controlled trial [ J ]. Lancet, 2007, 369 (9580) : 2161-2170.

同被引文献24

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部